Grace Therapeutics, Inc. (GRCE): Shareholders' Equity
$63.90M
As of 2026-03-31
$48.21M
As of 2026-06-30
-2.0%
3-year compound annual growth
+2.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $63.90M | -4.1% | 2026-06-18, Balance as of period end |
| 2025-03-31 | $66.61M | +7.9% | 2026-06-18, Balance as of period end |
| 2024-03-31 | $61.74M | -9.1% | 2025-06-23, Balance as of period end |
| 2023-03-31 | $67.95M | -37.2% | 2024-06-21, Balance as of period end |
| 2022-03-31 | $108.27M | +94.5% | 2023-06-23, Balance as of period end |
| 2021-03-31 | $55.66M | +328.4% | 2022-06-21, Balance as of period end |
| 2020-03-31 | $12.99M | +17.6% | 2021-06-22, Balance as of period end |
| 2019-03-31 | $11.04M | n/a | 2020-06-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $63.90M | -4.1% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $60.47M | -36.5% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $24.80M | -66.2% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $61.20M | +87.9% |
| Rallybio Corp (RLYB) | 2025-12-31 | $57.96M | -6.0% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $56.18M | -45.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $53.06M | -35.2% |
Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗